ERBB2 and breast cancer: CDK4/6 inhibitors are ATP-competitive inhibitors of cyclin-dependent kinases CDK4 and CDK6 that have shown efficacy for treatment of patients with hormone receptor (HR)+/HER2- advanced breast cancer [1].